Estrace Cream
Product Images NDC 50090-2321
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Estrace (NDC 50090-2321). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Table 2 -relative And Absolute Risk Seen In The Estrogen Plus Progestin Substudy Of Whi At An Average Of 5.6 Years A,b (Estrace Cream 02)
This is a comprehensive list detailing the risks associated with various health conditions such as non-fatal MI, ischemic stroke, deep vein thrombosis, pulmonary embolism, endometrial cancer, cervical cancer, hip and vertebral fractures, overall mortality, and global index. The data is adapted from multiple WHI publications and is based on centrally adjudicated data. The results include nominal confidence intervals and exclude certain events from the global index. The global index is defined by the occurrence of specific events such as CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, fractures, or death due to other causes. For more information, access www nhibi nih gov/whi.*
Allergan (Estrace Cream 03)
Label Image (Lbl500902321)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.